Zhitong Financial APP News, Rendu Biological (688193.SH) disclosed its half-yearly report in 2023 that the company's revenue during the reporting period was 80.03 million yuan, down 52.83% from the same period last year; the net profit loss of its parent was 10.19 million yuan, turning from profit to loss compared with the same period last year; deducting 14.56 million yuan from non-net profit loss from profit to loss compared with the same period last year; basic earnings per share-0.25 yuan.
During the reporting period, the company's business of traditional reagent products increased greatly, but it has not yet made up for the adverse impact caused by the sharp decline in epidemic prevention and control-related reagents and testing services, resulting in a 52.83% drop in total business income. In addition, in order to speed up the R & D progress and continue to strengthen R & D investment, the R & D investment during the reporting period increased by 26.76% compared with the same period last year, accounting for 23.24% of business income.